Send to

Choose Destination
Hum Gene Ther. 2008 Jun;19(6):601-8. doi: 10.1089/hum.2008.012.

Long-term benefit of adeno-associated virus/antisense-mediated exon skipping in dystrophic mice.

Author information

Department of Genetics and Molecular Biology, Institute Pasteur Cenci-Bolognetti, University of Rome La Sapienza, 00185 Rome, Italy.


Many mutations and deletions in the dystrophin gene, responsible for Duchenne muscular dystrophy (DMD), can be corrected at the posttranscriptional level by skipping specific exons. Here we show that long-term benefit can be obtained in the dystrophic mouse model through the use of adeno-associated viral vectors expressing antisense sequences: persistent exon skipping, dystrophin rescue, and functional benefit were observed 74 weeks after a single systemic administration. The therapeutic benefit was sufficient to preserve the muscle integrity of mice up to old age. These results indicate a possible long-term gene therapy treatment of the DMD pathology.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center